Does Antimalarial Drug Prevent COVID-19? New DGH Study Seeks Answers (Ruanne Barnabas, ICRC)

The benefits of hydroxychloroquine being investigated in multi-site clinical trial launching in April

Researchers are investigating whether hydroxychloroquine – a commonly used anti-malarial and autoimmune drug – can prevent COVID-19.

A multi-site clinical trial, led by the University of Washington Department of Global Health/International Clinical Research Center (ICRC)  in collaboration with NYU Grossman School of Medicine, aims to definitively determine whether hydroxychloroquine can prevent transmission in people exposed to the virus.

Match Day Goes Virtual (UW Medicine - Quotes August Longino)

The COVID-19 crisis has brought a whirlwind of changes that have impacted everyone in our community — including this year’s graduating class of medical students at UW School of Medicine. 

In the last few weeks, the students were pulled from their clinical rotations early.

Then, the difficult and unprecedented decision was made to hold the School’s Match Day ceremony online.

US Hospitals Could Be Overwhelmed in the Second Week of April (IHME)

In a forecast based on new data analyses, researchers find demand for ventilators and beds in US hospital intensive care units (ICUs) will far exceed capacity for COVID-19 patients as early as the second week of April. Deaths related to the current wave of COVID-19 in the US are likely to persist into July, even assuming people protect themselves and their communities by strongly adhering to social distancing measures and by taking other precautions advised by public health officials. 

Seattle Team Gets Funding to Start Human Trials of Potentially Groundbreaking Coronavirus Treatment (Seattle Times - Quotes Corey Casper)

Seattle’s Infectious Disease Research Institute has received seven-figure funding to begin human trials on a potentially groundbreaking novel coronavirus treatment.

The study could launch within weeks, take about 11 months to complete, and enroll about 100 patients diagnosed with a COVID-19 infection that’s causing moderate to severe pneumonia. It would deploy cancer-fighting NK-cells as an immunotherapy treatment for the coronavirus rather than the current approach of antiviral medication.

Pages